Neurocrine Biosciences (NBIX) Return on Capital Employed Growth (1y) (2012 - 2026)
Neurocrine Biosciences (NBIX) Return on Capital Employed Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.74 Bn | 86.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.87 Bn | 32.13 Bn | 1.97 Bn | 696.00 |
| 3 | Zoetis | 32.28 Bn | 30.34 Bn | 1.62 Bn | -507.00 |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn | -723.00 |
| 5 | United Therapeutics | 23.14 Bn | 20.98 Bn | 648.10 Mn | 89.00 |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.25 Bn | 18.44 Bn | 1.16 Bn | 944.00 |
| 8 | Neurocrine Biosciences | 17.89 Bn | 16.57 Bn | 800.70 Mn | 448.00 |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | 1,195.00 |
| 10 | Vireo Growth | 10.52 Bn | 10.37 Bn | 59.30 Mn | -679.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 448.00 |
| Dec 31, 2025 | -158.00 |
| Sep 30, 2025 | -336.00 |
| Jun 30, 2025 | -267.00 |
| Mar 31, 2025 | -197.00 |
| Dec 31, 2024 | 781.00 |
| Sep 30, 2024 | 935.00 |
| Jun 30, 2024 | 1,002.00 |
| Mar 31, 2024 | 1,091.00 |
| Dec 31, 2023 | -401.00 |
| Sep 30, 2023 | 313.00 |
| Jun 30, 2023 | 422.00 |
| Mar 31, 2023 | 262.00 |
| Dec 31, 2022 | 879.00 |
| Sep 30, 2022 | -508.00 |
| Jun 30, 2022 | -353.00 |
| Mar 31, 2022 | -448.00 |
| Dec 31, 2021 | -568.00 |
| Sep 30, 2021 | -363.00 |
| Jun 30, 2021 | -2,448.00 |